Rilonacept approved in the US for the treatment of recurrent pericarditis

Rilonacept is a recombinant fusion protein that blocks interleukin-1 (IL-1) alpha and IL-1 beta signalling. It’s approval for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children ≥12 was based on data from the Phase III RHAPSODY trial

Biospace Inc.